München Klinik gGmbH Schwabing Klinikum rechts der Isar der Technischen Universität Muenchen

The pediatric oncology department at the Munich site focuses on innovative studies for rhabdomyosarcoma, aiming to improve survival and reduce treatment toxicity.

• Evaluation of new systemic therapy combinations such as irinotecan‑based regimens
• Assessment of intensified radiotherapy approaches for metastatic disease
• Investigation of maintenance chemotherapy extensions to enhance long‑term outcomes
• Testing targeted agents like regorafenib in relapsed cases

These trials are conducted at München Klinik gGmbH Schwabing Klinikum rechts der Isar der Technischen Universität Muenchen, reflecting a commitment to advancing care for children with high‑risk sarcomas.

Research at the Munich pediatric hematology‑oncology unit investigates optimal chemotherapy and radiotherapy strategies for children with advanced renal tumors and metastatic spread.

• Comparison of pre‑operative versus post‑operative radiotherapy schedules
• Dose escalation of radiotherapy for high‑risk local disease
• Integration of novel drug combinations to improve metastatic response rates
• Evaluation of extended maintenance therapy to increase cure rates

The goal is to determine the most effective treatment pathways while preserving quality of life for young patients at this leading German research center.